MA56526A - Dérivés de pyrido [2,3-d] pyrimidine en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine - Google Patents

Dérivés de pyrido [2,3-d] pyrimidine en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine

Info

Publication number
MA56526A
MA56526A MA056526A MA56526A MA56526A MA 56526 A MA56526 A MA 56526A MA 056526 A MA056526 A MA 056526A MA 56526 A MA56526 A MA 56526A MA 56526 A MA56526 A MA 56526A
Authority
MA
Morocco
Prior art keywords
pyrido
inhibitors
immunodeficiency virus
human immunodeficiency
virus replication
Prior art date
Application number
MA056526A
Other languages
English (en)
Inventor
Eric P Gillis
Christiana Iwuagwu
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd
Publication of MA56526A publication Critical patent/MA56526A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA056526A 2019-06-19 2020-06-17 Dérivés de pyrido [2,3-d] pyrimidine en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine MA56526A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962863406P 2019-06-19 2019-06-19
PCT/IB2020/055653 WO2020254985A1 (fr) 2019-06-19 2020-06-17 Dérivés de pyrido [2,3-d] pyrimidine en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine

Publications (1)

Publication Number Publication Date
MA56526A true MA56526A (fr) 2022-04-27

Family

ID=71738195

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056526A MA56526A (fr) 2019-06-19 2020-06-17 Dérivés de pyrido [2,3-d] pyrimidine en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine

Country Status (25)

Country Link
US (1) US20210323967A1 (fr)
EP (1) EP3986561B1 (fr)
JP (1) JP2022537047A (fr)
KR (1) KR20220024608A (fr)
CN (1) CN114245795A (fr)
AR (1) AR119174A1 (fr)
AU (1) AU2020295793B2 (fr)
BR (1) BR112021025655A2 (fr)
CA (1) CA3143136A1 (fr)
CL (1) CL2021003388A1 (fr)
CO (1) CO2021017479A2 (fr)
CR (1) CR20210664A (fr)
DK (1) DK3986561T3 (fr)
FI (1) FI3986561T3 (fr)
IL (1) IL288750A (fr)
LT (1) LT3986561T (fr)
MA (1) MA56526A (fr)
MX (1) MX2021016149A (fr)
PE (1) PE20220510A1 (fr)
PT (1) PT3986561T (fr)
RS (1) RS65304B1 (fr)
SI (1) SI3986561T1 (fr)
TW (1) TW202115055A (fr)
UY (1) UY38755A (fr)
WO (1) WO2020254985A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3870577A1 (fr) 2018-10-24 2021-09-01 VIIV Healthcare UK (No.5) Limited Inhibiteurs de la réplication du virus de l'immunodéficience humaine
US20230045509A1 (en) * 2019-12-09 2023-02-09 Viiv Healthcare Company Pharmaceutical compositions comprising cabotegravir
CN115551858A (zh) * 2020-03-06 2022-12-30 Viiv保健英国第五有限公司 人类免疫缺陷病毒复制的抑制剂
KR20240074850A (ko) 2021-10-13 2024-05-28 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010000032A1 (fr) * 2008-07-02 2010-01-07 Avexa Limited Composés possédant des propriétés antivirales
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
JP6205354B2 (ja) 2011-07-06 2017-09-27 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のための化合物
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
WO2014110298A1 (fr) 2013-01-09 2014-07-17 Gilead Sciences, Inc. Hétéroaryles à 5 chaînons et leur utilisation comme agents antiviraux
PL2943493T3 (pl) 2013-01-09 2017-12-29 Gilead Sciences, Inc. Związki terapeutyczne do leczenia zakażeń wirusowych
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
WO2015130966A1 (fr) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Agents antiviraux
NZ729150A (en) 2014-08-29 2018-02-23 Gilead Sciences Inc Antiretroviral agents
BR122020001791B1 (pt) * 2016-08-19 2022-01-25 Gilead Sciences, Inc Usos de compostos terapêuticos no tratamento profilático ou terapêutico de uma infecção por vírus hiv
EP3507288B1 (fr) * 2016-09-02 2020-08-26 Gilead Sciences, Inc. Dérivés de 4,6-diamino-pyrido[3,2-d]pyrimidine en tant que modulateurs du recepteur de type toll
UY37710A (es) * 2017-05-02 2018-11-30 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
UY38559A (es) * 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana

Also Published As

Publication number Publication date
IL288750A (en) 2022-02-01
PT3986561T (pt) 2024-03-15
EP3986561A1 (fr) 2022-04-27
UY38755A (es) 2020-11-30
LT3986561T (lt) 2024-04-25
SI3986561T1 (sl) 2024-04-30
FI3986561T3 (fi) 2024-05-02
CR20210664A (es) 2022-01-21
AU2020295793B2 (en) 2023-07-06
AU2020295793A1 (en) 2022-01-20
BR112021025655A2 (pt) 2022-02-01
AR119174A1 (es) 2021-12-01
PE20220510A1 (es) 2022-04-07
WO2020254985A1 (fr) 2020-12-24
CO2021017479A2 (es) 2022-04-19
RS65304B1 (sr) 2024-04-30
KR20220024608A (ko) 2022-03-03
DK3986561T3 (da) 2024-03-04
TW202115055A (zh) 2021-04-16
JP2022537047A (ja) 2022-08-23
US20210323967A1 (en) 2021-10-21
CN114245795A (zh) 2022-03-25
CA3143136A1 (fr) 2020-12-24
CL2021003388A1 (es) 2022-09-30
MX2021016149A (es) 2022-05-18
EP3986561B1 (fr) 2024-02-14

Similar Documents

Publication Publication Date Title
MA56526A (fr) Dérivés de pyrido [2,3-d] pyrimidine en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
MA39985B1 (fr) 1h-pyrrolo [2,3-c]pyridine -7(6h)-ones et pyrazolo[3,4-c]pyridine-7(6h)-ones en tant qu'inhibiteurs de protéines bet
MA52987A (fr) Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak
EA201991693A1 (ru) Производное пиридина в качестве ингибитора ask1 и способ его получения и применения
CY1121649T1 (el) Ενωσεις 6,7-διυδροπυραζολο[1,5-α]πυραζιν-4(5η)-ονης και η χρηση τους ως αρνητικοι αλλοστερικοι τροποποιητες των υποδοχεων mglu2
EA201992082A1 (ru) Ингибитор поверхностного антигена вируса гепатита b
CY1119499T1 (el) Ενωσεις 6,7-διυδροπυραζολο[1,5-α]πυραζιν-4(5η)-ονης και η χρηση τους ως αρνητικοι αλλοστερικοι τροποποιητες των υποδοχεων mglur2
EA201692095A1 (ru) Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака
TR201905009T4 (tr) Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları.
HRP20202051T1 (hr) Aril supstituirani pirimidini za uporabu kod infekcije virusom influence
WO2017053216A3 (fr) Inhibiteurs nucléosidiques de la transcriptase inverse substitués en position 4' et préparations associées
EA202090258A3 (ru) Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний
EA201000090A1 (ru) Тризамещенные производные пиримидина для лечения пролиферативных заболеваний
EA201000092A1 (ru) Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний
CO6741203A2 (es) Derivados de biciclo[3,2,1]octilamida y sus usos
CY1121123T1 (el) Ενωσεις 6,7-διυδροπυραζολο[1,5-α]πυραζιν-4(5η)-ονης και η χρηση τους ως αρνητικοι αλλοστερικοι τροποποιητες των υποδοχεων mglu2
PE20211548A1 (es) Compuesto de triazina y su uso para fines medicos
MA43021A (fr) Nouveaux dérivés pyrrolo [2,3-d]pyrimidine utilisés en tant qu'inhibiteurs doubles de dyrk1/clk1
MA43583A (fr) Dérivés d'acide pentanoïque substitués par pyrrolo-[2,3-b]pyrimidne-pyridines pour traiter des infections par le virus de la grippe
EA202191498A1 (ru) 9-замещенные производные аминотриазолохиназолина в качестве антагонистов аденозиновых рецепторов, фармацевтические композиции и их применение
EA201992771A1 (ru) Ингибитор поверхностного антигена вируса гепатита b
UY32055A (es) Derivados sustituidos de la 5-Halo-N2-[sustituido](1-metil-1H-imidazol-4-il)pirimidin-2,-diamina y sus sales farmacéuticamente aceptables, procesos de preparación, composiciones y aplicaciones.
EA201692496A1 (ru) 6,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-4(5H)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ MGLUR2
BR112021011325A2 (pt) Derivados de rapamicina
CO2019013655A2 (es) Compuestos heterocíclicos bicíclicos sustituidos como inhibidores de la nadph oxidasa